No Data
China NT Pharma Narrows Annual Loss Despite Revenue Decline in 2025
NT PHARMA: ANNOUNCEMENT OF AUDITED ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2025
TaiLin Pharmaceutical (01011) expects a net loss of approximately RMB 10.9 million to RMB 15.9 million for the fiscal year 2025.
TaiLin Pharmaceutical (01011) announced that, following further discussions with the company's auditors during the audit process and based on the audit work completed by the auditors as of the date of this announcement, the board hereby further informs shareholders and potential investors that the group expects to recognize a one-time non-cash gain of approximately HKD 15.4 million (equivalent to RMB 14.1 million) from the issuance of new shares to settle debts. As a result, the expected loss for the group for the fiscal year ending December 31, 2025, will be further reduced by approximately HKD 15.4 million (equivalent to RMB 14.1 million) compared to the amount disclosed in previous announcements. The revised estimated net loss will range between approximately RMB 10.9 million and RMB 15.9 million.
NT PHARMA: PROFIT WARNING REDUCTION IN LOSS SUPPLEMENTAL ANNOUNCEMENT
China NT Pharma Sets March 31 Board Meeting to Approve 2025 Results and Consider Dividend
NT PHARMA: DATE OF BOARD MEETING
China NT Pharma Group Company Limited (HKG:1011) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough
